![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » The Immune Response Announces New Phase II NeuroVax Study
The Immune Response Announces New Phase II NeuroVax Study
The Immune Response, a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis (MS), has announced a new Phase II study to investigate the long-term safety, mechanism-of-action, and utility of a quarterly dosing regimen of NeuroVax, an investigational T-cell receptor peptide vaccine for multiple sclerosis.
NeuroVax is an immune-based therapy designed to specifically down-regulate the body's destructive immune responses observed in MS patients to alleviate the impact of the disease.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct